Skip to main content

Advertisement

Fig. 2 | Cancer Communications

Fig. 2

From: The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer

Fig. 2

Kaplan-Meier analysis-based estimation of PFS probabilities of metastatic breast cancer patients in the EMT and non-EMT groups. Patients in the EMT group met the combined criteria with a total CTC count equaled to or exceeded 10 per 5 mL peripheral blood and a proportion of M + CTCs surpassed 10.7%; Patients in the non-EMT group did not meet the criteria. PFS progression-free survival

Back to article page